Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing
Abstract Introduction Hidradenitis suppurativa (HS) is associated with inflammatory bowel disease (IBD). Using healthcare databases, an estimated 2.1% of patients with HS have IBD. Prospective screening of patients with HS with IBD sign/symptom-based questions and fecal calprotectin (FC) has not bee...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-05-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01438-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687959679270912 |
|---|---|
| author | Niamh Kearney Emily K. Pender Rosalind Hughes Collette McCourt Graham Turner Graham Morrison Glen Doherty Juliette Sheridan Donal O’Kane Brian Kirby |
| author_facet | Niamh Kearney Emily K. Pender Rosalind Hughes Collette McCourt Graham Turner Graham Morrison Glen Doherty Juliette Sheridan Donal O’Kane Brian Kirby |
| author_sort | Niamh Kearney |
| collection | DOAJ |
| description | Abstract Introduction Hidradenitis suppurativa (HS) is associated with inflammatory bowel disease (IBD). Using healthcare databases, an estimated 2.1% of patients with HS have IBD. Prospective screening of patients with HS with IBD sign/symptom-based questions and fecal calprotectin (FC) has not been studied. Our aim was to evaluate the prevalence of IBD in HS and the utility of a sign/symptom-based questionnaire and FC testing. Methods All patients with HS attending two clinics were invited to participate. Information was collected on demographics, HS severity, and IBD risk factors. Fecal samples were returned by patients for calprotectin testing (≤ 50 μg/g = negative, 50–150 μg/g = borderline, ≥ 150 μg/g = positive). Results We recruited 150 patients including 124 women (82.7%) with a median age of 36 years and Hurley stage 2/3 disease (88.6%); 11 patients had established IBD (7.3%). Up to 44.7% of patients reported gastrointestinal symptoms. In 98 patients who returned a fecal sample for calprotectin measurement, 10 had previously diagnosed IBD (10.3%), 81 had a negative FC (82.7%), 13 had a borderline FC (13.3%) and 4 had a positive FC (4.1%). Among 4 patients with a positive result, 2 had known IBD (50%); 2 without established IBD were referred to gastroenterology and 1 had a negative endoscopy reporting an acute diarrheal illness at the time of their FC. The second patient was diagnosed with endoscopic and histologic Crohn’s disease. Conclusions We report an IBD prevalence of 8%, higher than previous studies. Routine IBD sign/symptom-based assessment is currently recommended. In our study, this would result in a referral rate of 44.7%. Among 88 FC tests in patients without established IBD, 1 patient was diagnosed with incident occult Crohn’s disease. At a number needed to screen (NNS) of 88, routine evaluation of all patients with HS with FC may be justified especially prior to the use of interleukin (IL)-17 antagonists. |
| format | Article |
| id | doaj-art-70f6c424fc264c27ae51dd3db596f64c |
| institution | DOAJ |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-70f6c424fc264c27ae51dd3db596f64c2025-08-20T03:22:11ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-05-011571901191310.1007/s13555-025-01438-7Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin TestingNiamh Kearney0Emily K. Pender1Rosalind Hughes2Collette McCourt3Graham Turner4Graham Morrison5Glen Doherty6Juliette Sheridan7Donal O’Kane8Brian Kirby9Department of Dermatology, St. Vincent’s University HospitalDepartment of Dermatology, St. Vincent’s University HospitalDepartment of Dermatology, St. Vincent’s University HospitalDepartment of Dermatology, Belfast Health and Social Care TrustDepartment of Gastroenterology, Belfast Health and Social Care TrustDepartment of Gastroenterology, Belfast Health and Social Care TrustDepartment of Gastroenterology, St. Vincent’s University HospitalDepartment of Gastroenterology, St. Vincent’s University HospitalDepartment of Dermatology, Belfast Health and Social Care TrustDepartment of Dermatology, St. Vincent’s University HospitalAbstract Introduction Hidradenitis suppurativa (HS) is associated with inflammatory bowel disease (IBD). Using healthcare databases, an estimated 2.1% of patients with HS have IBD. Prospective screening of patients with HS with IBD sign/symptom-based questions and fecal calprotectin (FC) has not been studied. Our aim was to evaluate the prevalence of IBD in HS and the utility of a sign/symptom-based questionnaire and FC testing. Methods All patients with HS attending two clinics were invited to participate. Information was collected on demographics, HS severity, and IBD risk factors. Fecal samples were returned by patients for calprotectin testing (≤ 50 μg/g = negative, 50–150 μg/g = borderline, ≥ 150 μg/g = positive). Results We recruited 150 patients including 124 women (82.7%) with a median age of 36 years and Hurley stage 2/3 disease (88.6%); 11 patients had established IBD (7.3%). Up to 44.7% of patients reported gastrointestinal symptoms. In 98 patients who returned a fecal sample for calprotectin measurement, 10 had previously diagnosed IBD (10.3%), 81 had a negative FC (82.7%), 13 had a borderline FC (13.3%) and 4 had a positive FC (4.1%). Among 4 patients with a positive result, 2 had known IBD (50%); 2 without established IBD were referred to gastroenterology and 1 had a negative endoscopy reporting an acute diarrheal illness at the time of their FC. The second patient was diagnosed with endoscopic and histologic Crohn’s disease. Conclusions We report an IBD prevalence of 8%, higher than previous studies. Routine IBD sign/symptom-based assessment is currently recommended. In our study, this would result in a referral rate of 44.7%. Among 88 FC tests in patients without established IBD, 1 patient was diagnosed with incident occult Crohn’s disease. At a number needed to screen (NNS) of 88, routine evaluation of all patients with HS with FC may be justified especially prior to the use of interleukin (IL)-17 antagonists.https://doi.org/10.1007/s13555-025-01438-7Hidradenitis suppurativaInflammatory bowel diseaseFecal calprotectinScreening |
| spellingShingle | Niamh Kearney Emily K. Pender Rosalind Hughes Collette McCourt Graham Turner Graham Morrison Glen Doherty Juliette Sheridan Donal O’Kane Brian Kirby Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing Dermatology and Therapy Hidradenitis suppurativa Inflammatory bowel disease Fecal calprotectin Screening |
| title | Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing |
| title_full | Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing |
| title_fullStr | Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing |
| title_full_unstemmed | Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing |
| title_short | Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing |
| title_sort | inflammatory bowel disease prevalence in patients with hidradenitis suppurativa using prospective symptom based questionnaires and fecal calprotectin testing |
| topic | Hidradenitis suppurativa Inflammatory bowel disease Fecal calprotectin Screening |
| url | https://doi.org/10.1007/s13555-025-01438-7 |
| work_keys_str_mv | AT niamhkearney inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting AT emilykpender inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting AT rosalindhughes inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting AT collettemccourt inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting AT grahamturner inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting AT grahammorrison inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting AT glendoherty inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting AT juliettesheridan inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting AT donalokane inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting AT briankirby inflammatoryboweldiseaseprevalenceinpatientswithhidradenitissuppurativausingprospectivesymptombasedquestionnairesandfecalcalprotectintesting |